All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F25%3A10499293" target="_blank" >RIV/00064203:_____/25:10499293 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/25:10499293

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=i.OH-HTtCH" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=i.OH-HTtCH</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.jgo.2025.102304" target="_blank" >10.1016/j.jgo.2025.102304</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Assessing side-effect bother, burden, and tolerability: A qualitative study exploring the content validity of the Functional Assessment of Cancer Therapy - Item GP5

  • Original language description

    INTRODUCTION: Patient-reported measures of overall side effect burden such as the Functional Assessment of Cancer Therapy - item GP5 (GP5) can be used to assess the tolerability of cancer treatments. The single-item GP5, which reads &quot;I am bothered by side effects of treatment,&quot; has served as an endpoint in clinical trials. The objectives of this qualitative study were to explore how participants with medullary thyroid cancer (MTC) conceptualize side effect bother, burden, and tolerability and to generate evidence to support the GP5 as a fit-for-purpose measure of patient-reported tolerability in the treatment of MTC and to establish which response options constitute &quot;high side effect burden.&quot; MATERIALS AND METHODS: A purposive sample of 40 participants with MTC enrolled in the LIBRETTO-531 trial (NCT04211337) were recruited via clinical trial sites. Semi-structured interviews were conducted in the participant&apos;s preferred language to examine the concept of tolerability, demonstrate understanding of the GP5 content, and establish which response options constitute &quot;high side effect burden.&quot; Interview transcripts were thematically analyzed with a mix of inductive and deductive coding methods. RESULTS: In concept elicitation interviews, patients reported side effect bother as a highly relevant concept that was among the most proximal concepts to tolerability. The experience of side effects that are symptomatic and bothersome or burdensome are key contributors to how patients perceive the tolerability of a treatment. Cognitive interviewing showed the GP5 item was clear and understandable to all participants. Participants reported clear and concrete meaningful differences between each response option. Importantly, the qualitative data provide evidence that &quot;high side effect burden&quot; aligns with the response options of &quot;Quite a bit&quot; and &quot;Very much&quot; (score of 3 and 4, respectively) for most (60 %, n = 24) interview participants. DISCUSSION: Participants described the concepts of side effect bother, side effect burden, and tolerability as highly relevant and related. The GP5 assesses a concept important to individuals undergoing treatment for MTC in a way that is understandable and relevant. The definition of &quot;high side effect burden&quot; is appropriately reflected by scores of 3 or 4. This qualitative evidence is supportive of the GP5 as a fit-for-purpose measure of comparative tolerability in MTC.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2025

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Geriatric Oncology

  • ISSN

    1879-4068

  • e-ISSN

    1879-4076

  • Volume of the periodical

    16

  • Issue of the periodical within the volume

    7

  • Country of publishing house

    NL - THE KINGDOM OF THE NETHERLANDS

  • Number of pages

    9

  • Pages from-to

    102304

  • UT code for WoS article

    001527991900001

  • EID of the result in the Scopus database

    2-s2.0-105009750715